We investigated the influence of organ-specific parameters on tolerance and immunity to human MUC1. C57Bl/6 mice (wild-type) and C57Bl/6 transgenic for MUC1 (MUC1.Tg) were challenged in the pancreas with Panc02-MUC1, a C57Bl/6-syngeneic pancreatic cancer cell line expressing human MUC1. Wild-type mice produced immune responses to MUC1 when presented on tumor cells growing in the pancreas; however, the responses to tumors in the pancreas were less effective than responses produced by tumor challenge at the s.c. 
Introduction
The prognosis for pancreatic cancer remains unfavorable (1).
series of experiments to determine the feasibility of developing tumor vaccines that produce immune responses against forms Surgical procedures are effective against early lesions that have not metastasized; however, virtually all patients with of MUC1 expressed on pancreatic cancer cells that may not be present on normal ductal epithelia. pancreatic cancer have non-operable disease at diagnosis. Chemotherapy is ineffective and radiotherapy is of limited One factor often not considered during evaluation of tumor vaccines is organ site of the primary tumor or metastatic curative value. Immunotherapeutic strategies including the use of defined tumor vaccines are under investigation as lesions. The pancreas has a microenvironment that differs from other organ sites, and includes unique features of adjunctive therapies for treating pancreatic cancer (2-5). One candidate target antigen for use in pancreatic cancer vaccines cellularity, vascularity and lymphatic accessibility. Moreover, the pancreas is both an endocrine and exocrine organ is MUC1, a human epithelial mucin expressed on secretory epithelia of the pancreas and other organs. Most pancreatic that produces locally high concentrations of a number of hormones, cytokines and secretory products related to digestumors overexpress MUC1 (6). In addition, MUC1 expressed by pancreatic tumor cells is aberrantly glycosylated compared tion. The influence of these locally produced factors on tumor immune responses, including the ability of immune effector to normal epithelia of the pancreatic duct, as evidenced by the appearance of tumor-associated oligosaccharide structures cells and molecules to penetrate and kill tumors at different sites, is poorly understood. Most previously described models such as sialyl Tn (7). This has led us and others to undertake a to evaluate tumor immunotherapy utilize s.c. sites of tumor Methods challenge or lung colonization following i.v. injection of tumor Mice cells. These organ sites (s.c. and lung) are unusual from the C57BL/6 female mice (8-10 weeks old) were purchased from immunological perspective in that they contain relatively high Jackson Laboratories (Bar Harbor, ME). MUC1.Tg C57BL/6 numbers of antigen-presenting cells, they are frequented by (MUC1.Tg) mice were previously described (9). Female circulating lymphocytes, and they are well provisioned with MUC1.Tg mice were obtained from a breeding colony at the lymphatics and blood vessels. It is not known if mechanisms University of Nebraska Medical Center. of immunity that protect against tumors at s.c. sites are effective at organ-specific locations such as the pancreas.
Tumor cells and injection procedures Another factor not widely investigated is the influence of
The pancreatic tumor cell line Panc02, which is syngeneic to immunological tolerance on immune responses to tumor C57BL/6 mice, was obtained from Dr J. Nelson (University of antigens that are also expressed on adjoining normal cells in Texas M. D. Anderson Cancer Center) (10). This cell line was the pancreas. The inter-relationships between tolerance and maintained in McCoy's 5A media with 10% FBS and no immunity, normal anatomical and cellular expression patterns antibiotics. Panc02 was transfected with an expression vector of antigens, and expression of antigens on tumors are not for the human MUC1 cDNA (7). Cloned lines constitutively well understood. For example, MUC1 is expressed on the expressing MUC1 were selected as described previously (8). apical side of normal ductal epithelia of pancreas and other A cell line expressing high levels of MUC1 was used in the secretory epithelia, an anatomical location that can be considstudies reported here and is designated Panc02-MUC1. A ered to be external to the body and possibly sequestered cloned control cell line transfected with vector alone was from antibodies and circulating immune effector cells. The named Panc02-neo. accessibility to circulating lymphocytes of MHC molecules Subcutaneous tumor challenge was performed as previexpressed on ductal epithelia is not well described. Disruption ously described (9). Briefly, 1ϫ10 6 tumor cells (unless otherof the differentiated structure of the pancreas by a developing wise indicated) were injected s.c. and tumor growth was adenocarcinoma (which is believed to be derived from the quantified by calculating tumor volume over time. The experiductal epithelia) results in the cell surface exposure of antigens mental endpoint (death) was defined as the time point at and MHC molecules to the interorgan space in which immune which tumor volume reached 1 cm 3 , whereupon the animals cells may traffic. Released or secreted antigens such as were euthanized. MUC1 may enter circulation, bind to other cells in the region Orthotopic injection of the tumor suspension into the panof the tumor, and affect immune responses and other local creas was performed as previously described (8). Briefly, biological processes.
suspensions of 1ϫ10 5 tumor cells were prepared by harIn humans, it has been impossible to investigate the intervesting the cultured cells in vitro and resuspending the cells in McCoy's 5A media with no additives. Mice were play between parameters of tumor growth, immunological anesthetized and the pancreas was exposed by traction tolerance and the development of anti-tumor responses. It through a median incision in the upper abdomen. Then 30 µl has also been impossible to evaluate the development of of the tumor suspension was injected into the gastric lobe of autoimmune responses that may result from effective vaccinathe pancreas. The abdomen was then closed in two layers. tion with antigens that are common to tumors and normal
The experimental endpoint (death) was defined as the time cells. Thus, we developed animal model systems to investigate point at which mice developed a distended abdomen due to organ-specific effects on tolerance and tumor immunity. One ascites or exhibited moribund behavior, at which time the model of pancreatic tumor growth includes orthotopic injection animals were euthanized and examined. Tumor growth of of a syngeneic pancreas cancer cell line into the pancreas 1 cm 3 or greater in these animals was confirmed by gross of C57Bl/6 mice (8), which can be used to evaluate tumor and microscopic examination of euthanized animals. immunity to MUC1 in the context of tumor growth in the Statistical differences between survival for all groups of microenvironment of the pancreas. A second (complementary) animals were calculated using the log-rank test. model system utilizes a C57Bl/6 strain of mice that is transgenic for human MUC1 and congenic to wild-type C57Bl/6 mice (9), Cellular adoptive transfer which allows us to investigate immunity and tolerance to Spleens and axillary lymph nodes were harvested from donor MUC1 in the context of an animal strain that shows normal mice that were previously challenged s.c. with 1ϫ10 6 cells temporal and spatial expression of MUC1.
of Panc02-MUC1. Spleens and lymph nodes were manually In the study reported here, we investigated by in vivo and mechanically processed to yield a single-cell suspension. methods the nature of the immune response that rejects Aliquots equivalent to one-half of the total cell suspension MUC1-expressing pancreatic tumor cells at both s.c. and from one donor mouse were injected i.p. into each recipient orthotopic sites. We established that MUC1-specific CD8 ϩ wild-type or MUC1.Tg mouse using established procedures cells are required to reject pancreatic tumors at s.c. sites and (11). One day later, an orthotopic injection of tumor cell that these CD8 ϩ cells can reject pancreatic tumors growing suspension containing 1ϫ10 5 cells of Panc02-MUC1 or in the pancreas. Furthermore, MUC1 transgenic mice are Panc02-neo was performed. immunologically tolerant to MUC1 and demonstrated that Depletion of CD4 ϩ /CD8 ϩ T lymphocytes immunity against pancreatic tumors expressing MUC1 could be adoptively transferred to the MUC1 transgenic mice from Rat anti-mouse hybridoma clones GK1.5 (anti-CD4), 53-6.72 (anti-CD8) and SFR3-DR5 (control antibodies) were wild-type mice immunized at the s.c. site.
wild-type C57Bl/6 mice (70%) challenged at the s.c. site, whereas control Panc02 cells expressing only the product of the neomycin-resistance gene grow progressively in a majority of wild-type mice. MUC1.Tg mice allowed progressive tumor growth for both Panc02-MUC1 and Panc02-neo, resulting in survival curves that were indistinguishable from each other and from the survival curve of wild-type mice challenged with Panc02-neo. These data demonstrate that MUC1 is an immunodominant xenoantigen when expressed on Panc02 cells. MUC1-specific immune responses in wild-type C57Bl/6 reject Panc02-MUC1 tumors at the s.c. site. MUC1.Tg mice are immunologically unresponsive (tolerant) to MUC1. The data showing equivalent growth rates for Panc02-neo and Panc02-MUC1 in MUC1.Tg mice suggest that MUC1 expression has not affected the growth rates or properties of these tumors in vivo.
Data presented in Fig. 1 (b) demonstrate that both Panc02-neo and Panc02-MUC1 tumor cells show growth properties in the pancreas that are more aggressive than those observed at the s.c. site. Similar to the s.c. site, Panc02 tumors growing in the pancreas of wild-type mice elicited MUC1-specific immune responses that were not observed in the MUC1.Tg Wild-type mice were immunized s.c. with 1ϫ10 5 cells of Panc02-MUC1. Three weeks later, these mice and control mice (no immunization) were challenged intrapancreatically purchased from ATCC (Rockville, MD), and cultured in vitro with 1ϫ10 5 Panc02-MUC1 cells (Fig. 2a) or Panc02-neo according to product sheet specifications. Hybridoma culture cells (Fig. 2b ). Data presented in Fig. 2 (a) show that mice supernatants were filtered and each mAb was purified on a immunized with Panc02-MUC1 developed no tumors at the Protein G-Sepharose Fast Flow system (Pharmacia Biotech, pancreatic site, whereas non-immunized mice developed Uppsala, Sweden). mAb were bound to the column in the tumors and showed poor survival after orthotopic challenge presence of 20 mM Na 2 HPO 4 , pH 7.0 and elution was with Panc02-MUC1 (P Ͻ 0.0001). Thus, s.c. immunization accomplished by using 100 mM glycine, pH 2.7. Eluted with Panc02-MUC1 provided protection against subsequent solutions were immediately neutralized using 1 M Tris, pH 9.0, challenge with Panc02-MUC1 in the pancreas. at a 1:25 ratio. Rat Ig was quantified by solid-phase ELISA The data presented in Fig. 2(b) demonstrate that immunity to as described previously (10). Three courses of i.p. injection Panc02-MUC1 was specific for MUC1, since s.c. immunization of 0.5 mg of GK1.5, 53-6.72, both or SFR3-DR5 on days with Panc02-MUC1 did not provide significant protection -6, -4 and -2 were administered to deplete CD4 ϩ CD8 ϩ , against intrapancreatic challenge with Panc02-neo: there was CD4 ϩ and CD8 ϩ cells respectively. Depletion of lymphocytes no statistically significant (P ϭ 0.09) difference in the survival was confirmed in representative animals by flow cytometry at curves shown in Fig. 2(b) . Thus, Panc02 expressing the day -1. Spleen and lymph node cells were incubated with rat neomycin-resistance gene remains poorly immunogenic and anti-mouse CD4, anti-mouse CD8, anti-mouse CD3 or antithe tumor immunity observed in the data presented in Fig. 2 (Fig. 3a) or Panc02-neo (Fig. 3b) . As shown in Fig. 3(a) , a Data presented in Fig. 1(a) demonstrate that Panc02 tumors expressing MUC1 are rejected by a substantial proportion of degree of tumor immunity was conferred on the recipient mice as evidenced by significantly improved survival in the group of mice that received the adoptive transfer of cells from adoptively transferred to MUC1.Tg recipient mice. A negative control for this experiment was adoptive transfer of cells from immune animals, as compared with the group of mice that received adoptive transfer of naive cells (P ϭ 0.0044). This non-immunized wild-type mice into a group of MUC1.Tg recipient mice. On the following day, recipient mice were shows that adoptive transfer of immune cells from wild-type donors is effective in protecting wild-type recipients against challenged in the pancreas with 1ϫ10 5 cells of Panc02-MUC1 (Fig. 4a) or Panc02-neo cells (Fig. 4b) . As shown in Fig. 4(a) , intrapancreatic challenge of Panc02-MUC1.
Data presented in Fig. 3(b) demonstrate that adoptive the group of MUC1.Tg mice that received an adoptive transfer of immune cells from wild-type donors had significantly better transfer of cells from Panc02-MUC1-immunized mice conferred immunity specific for MUC1, since no immune survival than a control group of mice that received an adoptive transfer of naive cells (P ϭ 0.045). This demonstrates that protection was afforded mice challenged with Panc02-neo. In addition, the data in Fig. 3(b) demonstrate that the immune adoptive transfer of immune cells from wild-type donors provides some immunological protection to MUC1.Tg recipiprotection resulted from immunization with Panc02-MUC1 cells, since adoptive transfer of naive cells had no effect on ents against intrapancreatic challenge of Panc02-MUC1. As shown in Fig. 4(b and not immunity to other tumor-associated antigens expressed on Panc02 cells. The data shown in Fig. 1 suggested that MUC1.Tg animals were immunologically tolerant to Panc02-MUC1 tumor cells.
Adoptive transfer of immune cells from MUC1.Tg mice was It was of interest to determine if tumor immunity could be
not effective in prolonging survival of wild-type mice adoptively transferred from wild-type animals into MUC1.Tg mice. Wild-type donor mice were immunized s.c. with 1ϫ10 6 The data in Fig. 1 and previously published data (9,11) support the hypothesis that MUC1.Tg mice are immunoloPanc02-MUC1 cells. Three weeks later, immune cells from spleens and lymph nodes of these wild-type donors were gically tolerant to MUC1; however, the mechanism of tolerance mice showed a slightly decreased survival as compared to the negative control group of mice (mean survival: 49 versus 55 days), though the difference was not statistically significant (P ϭ 0.133). These results suggest that cells of the MUC1.Tg to MUC1 is poorly understood. Previously, we analyzed the frequency of MUC1-specific cytotoxic T lymphocytes (CTL) mice do not mediate anti-tumor immune responses when adoptively transferred into wild-type recipient mice. in immunized wild-type and MUC1.Tg mice and found no statistically significant differences in the responses detected Both CD4 ϩ and CD8 ϩ T cells play a role in cell-mediated in vitro between wild-type and MUC1.Tg mice (11). This immunity against Panc02-MUC1 cells in the pancreas suggested that MUC1.Tg animals retained some capacity to respond to MUC1 in vitro. From this it can be hypothesized Antibody-mediated immune responses are ineffective for rejection of Panc-02-MUC1 tumors (8). Thus, we hypothesized that not all of the observed tolerance to MUC1 results from clonal deletion and that at least a portion of the tolerance that a population of T cells was responsible for MUC1-specific tumor rejection. Depletion of specific T cell populations was observed in the MUC1.Tg mice is mediated by peripheral mechanisms of tolerance. We therefore sought to determine accomplished by i.p. injection of wild-type mice with antibodies against CD4 and/or CD8 using established procedwhether or not MUC1.Tg mice produce immune responses against Panc02-MUC1 that can be detected in vivo by adoptures, as described in Methods. Cellular depletion of specific T cell populations for each group of mice was confirmed by ive transfer into wild-type mice. MUC1.Tg donor mice were immunized s.c. with 1ϫ10 6 Panc02-MUC1 cells. Three weeks flow cytometric analysis of one mouse per group, 1 day before intrapancreatic tumor challenge. The results indicated later, spleen and lymph node cells were adoptively transferred from these MUC1.Tg donors to wild-type recipient mice. As that Ͻ1% of CD4 ϩ and/or CD8 ϩ cells remained in depleted mice, demonstrating that depletion was effective (data not controls, adoptive transfer of naive cells from unmanipulated MUC1.Tg mice to wild-type recipient mice were performed.
shown). As shown in Fig. 6(a) , mortality from tumor growth was greater but did not achieve statistical significance) for Recipient mice were challenged in the pancreas with 1ϫ10 5 cells of Panc02-MUC1 (Fig. 5a ) or Panc02-neo cells (Fig. 5b) .
CD4-depleted (P ϭ 0.113) mice and it was statistically greater for CD8-depleted (P ϭ 0.0439) mice, as compared to control There were no significant differences in survival (following orthotopic challenge with either Panc02-MUC1 or Panc02-mice. The group depleted of both CD4 ϩ and CD8 ϩ cells showed the poorest survival (P ϭ 0.0097) suggesting that neo) of recipients that received adoptive transfer of cells from MUC1.Tg donors and mice that received adoptive transfer of tumor growth and mortality in mice depleted of both CD4 ϩ and CD8 ϩ cells was similar to that of MUC1.Tg mice. This naive cells. In fact, recipients of immune cells from MUC1.Tg and it is aberrantly glycosylated by tumors as compared to corresponding normal tissues (7,13).
We asked whether immunization at the s.c. site would protect mice against tumors growing in the pancreas. In wildtype mice, injection of Panc02-MUC1 cells into the pancreas resulted in tumors with aggressive growth properties (Fig. 1) that were less immunogenic than corresponding tumors grown at the s.c. site. Panc02-MUC1 tumor growth was more aggressive in MUC1.Tg mice (Fig. 1) , because of immunological tolerance to MUC1 (10). Subcutaneous challenge with Panc02-MUC1 cells produced an immune response to MUC1 that protected against subsequent intrapancreatic challenge (Fig. 2) in wild-type mice, suggesting that immune responses to MUC1 produced at the s.c. site were capable of rejecting tumors growing in the pancreatic environment.
We sought evidence of a cellular immune response to MUC1 expressed on Panc02, in light of previous findings suggesting that antibody responses do not protect against pancreatic tumor growth (8). Similar to previous findings using the B16 melanoma cell line (11), in vitro assays of cytotoxic T cell activity were not informative regarding the tumor immune status of mice challenged with Panc02-MUC1 (data not Panc02-MUC1 (Fig. 3) . No increase was observed in survival of recipient wild-type mice challenged with Panc02-neo, demonstrating that immune responses to non-MUC1 tumor antigens are a minor factor in the anti-tumor responses. In supports the hypothesis that both CD4 ϩ and CD8 ϩ contribute to rejection of Panc02-MUC1 tumors in the pancreas.
addition, adoptive transfer of immune cells from donor wild-type mice previously immunized with Panc02-MUC1 pro-A similar experimental design was used to investigate the nature of the response induced in the s.c. model of tumor longed survival of MUC1.Tg mice. Control MUC1.Tg mice that received cells from unprimed wild-type animals were challenge. Groups of CD4 ϩ -and CD8 ϩ -depleted mice were challenged s.c. with 1ϫ10 6 cells of Panc02-MUC1. As shown unresponsive to MUC1. The molecular phenotypes of cellular responses to Panc02-in Fig. 6(b) , depletion of CD4 ϩ cells alone did not affect rejection of the tumor at the s.c. site, since all animals rejected MUC1 in wild-type mice were investigated by performing antibody-mediated T cell depletion studies. The results Panc02-MUC1 tumors. Depletion of CD8 ϩ cells significantly (P ϭ 0.0068) decreased survival in this group. Depletion of showed that CD8 ϩ cells were required for rejection of Panc02-MUC1 tumors at the s.c. site. Elimination of CD4 ϩ cells did both CD4 ϩ and CD8 ϩ cells further decreased survival (P ϭ 0.0001). Taken together, these findings suggest that not significantly reduce immunity to MUC1 expressed on Panc02-MUC1 cells at the s.c. site; however, CD4 ϩ cells CD8 ϩ cells are primarily required for immune rejection of Panc02-MUC1 cells at the s.c. site and that CD4 ϩ cells probably play a role in immunity at this site since elimination of both CD4 ϩ and CD8 ϩ cells decreased the survival of wildcontribute to tumor rejection when CD8 ϩ cells are present.
type mice to an extent that was significantly worse than mice only depleted of CD8 ϩ cells (Fig. 6 ).
Discussion
These results are in contrast to previous results obtained when the B16.MUC1 melanoma cell line was used for tumor One goal of our studies was to understand parameters that contribute to effective vaccination against pancreatic cancer. challenge at the s.c. site (11). CD4 ϩ but not CD8 ϩ cells were required for rejection of this melanoma cell line (11). This There are no previously reported studies that investigated the influence of the pancreatic organ site on immunity to a specific response was not detected by in vitro assays, but instead was detected by in vivo assays of tumor rejection following tumor antigen in the context of immunological tolerance, which is one subject of this report. Orthotopic implantation of adoptive transfer of immune cells and/or in vivo antibody depletion of selected cellular populations. Although the mechtumor cells in mice provides an improved model for growth of tumor cells that includes rapid growth of local tumor anism of CD4 ϩ -mediated rejection of B16.MUC1 cells is not known, it is likely that CD4 ϩ effector cells recognize MUC1 and the development of spontaneous metastases (12) . We investigated immune responses to the tumor-associated antipeptides associated with class II MHC molecules. The CD8 ϩ effector cells that mediate rejection of Panc02-MUC1 cells gen MUC1, which has been a component of several human tumor vaccine trials. MUC1 is a useful target of immunotherapy are predicted to recognize antigen in the context of MHC class I molecules. Taken together, these results suggest that because it is overexpressed in most pancreatic tumors (6) distinct mechanisms of cellular immunity to the specific tumor factors, none of which are well understood in the context of different organ sites. The local environment at different organ antigen MUC1 are produced at the s.c. site and that the type of response produced to MUC1 is in part determined by the sites may affect the properties of tumors that grow at those sites. For example, factors that may be present at locally high tumor on which the antigen is expressed.
It should be noted that our findings regarding CD8-mediated concentrations in the pancreas (cytokines, hormones, cellular interactions) may up-regulate or down-regulate expression of tumor immune responses to MUC1 cells are consistent with those of other investigators (14) , who observed that CD8 ϩ molecules on the tumor cells that are related to antigen recognition or immune destruction of the tumor cells (MHC T cells were responsible for MUC1-specific tumor immunity against a different tumor cell line challenged at the s.c. site class I and II, Fas ligand, and receptors for tumor necrosis factor and TRAIL). Alternatively, the activity of some T cells (15, 16) . Interestingly, CD4 ϩ cells (17) reactive with MUC1 have also been detected by in vitro assays of CTL activity from or accessory cells required for immune responses may be altered by such a microenvironment (22). These parameters human patients with different adenocarcinomas, although the in vivo activity of these cells has not been established.
of tumor immunity should be investigated further in future studies and principles gleaned from these studies should be The cells that mediate rejection of Panc02-MUC1 tumors at the pancreatic site were also evaluated by antibodyapplied to clinical trials in humans. mediated T cell-depletion studies (Fig. 6 ). Both CD4 ϩ and CD8 ϩ T cells contributed to MUC1-specific tumor immunity Acknowledgements at the pancreatic site of wild-type mice (Fig. 6) . The findings that CD4 ϩ and CD8 ϩ cells are required for rejection at the 
